Filana Therapeutics Inc PX91
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 48.31M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.filanatx.com
Valuation
|
Metric
|
PX91
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.60 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PX91
|
|---|---|
Quick Ratio | 2.06 |
Current Ratio | 2.08 |
Interest Coverage | — |
Quick Ratio
PX91
Profitability
|
Metric
|
PX91
|
|---|---|
Return on Assets (Normalized) | −20.45% |
Return on Equity (Normalized) | −32.43% |
Return on Invested Capital (Normalized) | −37.32% |
Return on Assets
PX91
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DP!bS& | LOCK|<Kbch | $127B | |||
| Moderna Inc
MRNA
| LOCK|dCPDs# | LOCK|f?S | $91B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|XdZvJJ | LOCK|khRf@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|#T?nGL | LOCK|hc | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|b??my$c | LOCK|Bdd | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^v!%!Pw | LOCK|J^KQ% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^w^N<<! | LOCK|PzJP< | $27B | |||
| Incyte Corp
INCY
| LOCK|%Kh!H> | LOCK|Q! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@G^L@p? | LOCK|t^R | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<GHv&R& | LOCK|<># | $14B |
United States